Minnesota is entering a new phase in the debate over psychedelic policy. Psychedelics such as psilocybin remain controlled substances, but state lawmakers have spent the past several years examining whether Minnesota should create a legal framework for therapeutic access. In 2026, that discussion moved forward when the Legislature directed the Office of Cannabis Management to develop recommendations for a potential psilocybin therapeutic-use program.
Where Minnesota Law Stands Today
Psilocybin is not currently legal for general or therapeutic use in Minnesota. Under Minnesota law, psilocybin and psilocin remain Schedule I controlled substances. Although lawmakers considered proposals in 2026 that would have established a regulated therapeutic-use program, the program itself was not enacted. Instead, the Legislature directed the Minnesota Office of Cannabis Management to study how such a program could operate and publish recommendations by January 15, 2027.
How Minnesota Got Here
Minnesota’s current debate grew out of the Psychedelic Medicine Task Force, which the Legislature created in 2023 to examine the legal, medical, and policy issues surrounding potential legalization. The task force focused on psilocybin, MDMA, and LSD, reviewed scientific research, heard from experts and stakeholders, and examined regulatory approaches used in other states. It submitted its final legislative report in January 2025, providing lawmakers with findings and recommendations that continue to shape Minnesota’s approach to psychedelic policy.
What Changed in 2026
In 2026, Minnesota lawmakers considered proposals that would have gone further by creating a regulated psilocybin therapeutic-use program. The approach that ultimately became law was narrower. Rather than legalizing therapeutic psilocybin, lawmakers required the Office of Cannabis Management to develop recommendations for how a future program could work. The report must examine the feasibility of a program for adults age 21 and older with qualifying medical conditions, including supervised use with a facilitator at a treatment facility. The recommendations are due January 15, 2027.
What Happens Next
The next major milestone is January 15, 2027, when the Minnesota Office of Cannabis Management must publish its recommendations for a potential psilocybin therapeutic-use program. The report is required to address whether such a program is feasible, how qualifying medical conditions could be determined and updated, and how a program could be developed and administered. The office must also continue examining whether federal funding could support state efforts in this area. After the report is submitted, any decision to actually establish a therapeutic-use program would require further action; the 2026 law does not automatically legalize psilocybin or create the program.
What Minnesota Psychedelics Will Be Watching
Minnesota Psychedelics will continue following the Office of Cannabis Management’s work ahead of the January 2027 report, along with new legislation, regulatory proposals, clinical research, and other developments affecting psychedelic policy in the state. As Minnesota’s approach evolves, we’ll track what changes, what doesn’t, and what those developments could mean for patients, providers, researchers, and the public.
Leave a comment